Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

Abstract The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating...

Full description

Bibliographic Details
Main Authors:	Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson, Prudence Kgagudi, Nonkululeko Mzindle, Haajira Kaldine, Carol Crowther, Glenda Gray, Linda-Gail Bekker, Novavax trial clinical lead author group, Vivek Shinde, Chijioke Bennett, Gregory M. Glenn, Shabir A. Madhi, Penny L. Moore
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-01-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-27698-x

Similar Items

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
by: Eddie Underwood, et al.
Published: (2023-12-01)

Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
by: Diego Macías Saint-Gerons, et al.
Published: (2023-02-01)

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
by: Heath, PT, et al.
Published: (2021)

Protein vaccine NVX-CoV2373 elicits functional T cell immunity
by: Pengcheng Zhou
Published: (2022-10-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

Angioedema‐like eyelid edema following the second NVX‐CoV2373 COVID‐19 vaccination
by: Mari Matsumoto, et al.
Published: (2023-10-01)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
by: Kirsten E. Lyke, et al.
Published: (2023-07-01)

NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
by: Franz Mai, et al.
Published: (2024-03-01)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines
by: Toback, S, et al.
Published: (2021)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
by: Jing-Hui Tian, et al.
Published: (2021-01-01)

Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
by: Heath, PT, et al.
Published: (2022)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
by: Carolyn Rydyznski Moderbacher, et al.
Published: (2022-10-01)

2373
by: Serena-Kaye Kinley-Cooper, et al.
Published: (2017-09-01)

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
by: Anthony M. Marchese, et al.
Published: (2023-12-01)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Lauffenburger, Douglas
Published: (2023)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Matthew J. Gorman, et al.
Published: (2021-09-01)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies.
by: Cathrine Scheepers, et al.
Published: (2022-09-01)

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context
by: Prasad S. Kulkarni, et al.
Published: (2023-03-01)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
by: Magdalena Mueller-Enz, et al.
Published: (2023-07-01)

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
by: Thandeka Moyo-Gwete, et al.
Published: (2022-10-01)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
by: Tetsuo Nakayama, et al.
Published: (2023-11-01)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
by: Neil Formica, et al.
Published: (2021-10-01)

Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax; a Systematic Review
by: Omid Dadras, et al.
Published: (2022-07-01)

Treatment of Swine Closed Head Injury with Perfluorocarbon NVX-428
by: Francoise Arnaud, et al.
Published: (2020-09-01)

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
by: Boitumelo M. Motsoeneng, et al.
Published: (2023-08-01)

Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
by: Klara Lenart, et al.
Published: (2024-01-01)

Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses
by: Lisa A. Weber, et al.
Published: (2021-11-01)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
by: Xiaomei Zhang, et al.
Published: (2023-08-01)

In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer.
by: Lisa Annabel Weber, et al.
Published: (2020-01-01)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
by: Nonhlanhla N Mkhize, et al.
Published: (2023-06-01)

NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.
by: Alexandra Hebar, et al.
Published: (2012-01-01)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)

Be Your Sister’s Keeper: Personal Experience of Travelling a Lonely Journey in Academia
by: Duduzile Mzindle
Published: (2024-02-01)

Be Your Sister’s Keeper: Personal Experience of Travelling a Lonely Journey in Academia
by: Duduzile Mzindle
Published: (2024-02-01)

Be Your Sister’s Keeper: Personal Experience of Travelling a Lonely Journey in Academia
by: Duduzile Mzindle
Published: (2024-02-01)

Chronic Fatigue Syndrome: Where Do Your Views Lie? An Experience from a UK Medical Student
by: Rebecca L. Lambson
Published: (2015-06-01)

Sequence and functional characterization of a public HIV-specific antibody clonotype
by: Amyn A. Murji, et al.
Published: (2022-01-01)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
by: Simone I. Richardson, et al.
Published: (2021-09-01)

Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage
by: Cathrine Scheepers, et al.
Published: (2022-04-01)

Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage.
by: David Sacks, et al.
Published: (2019-09-01)